Baltimore-For patients with total PSA levels in the range of 2.5 to 4.0 ng/mL, measuring the proportion of precursor forms of PSA (pPSA) relative to free PSA (fPSA) may significantly lower the number of unnecessary biopsies compared with measuring percent-free PSA (%fPSA) alone, a new study suggests.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.